As with many cutting-edge technologies, the mass spectrometry marketplace comes flush with options, acronyms, and jargon, making it difficult for consumers to choose the system that's right for them. According to Philip Gafken, director of the Fred Hutchinson Cancer Research Center Proteomics Shared Resource in Seattle, it all comes down to application. "Believe it or not, it doesn't dawn on people that they should be looking closely at application. They don't really pay close attention to what they'll be using it for."






